<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
<journal-title>Frontiers in Genetics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Genet.</abbrev-journal-title>
<issn pub-type="epub">1664-8021</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">774432</article-id>
<article-id pub-id-type="doi">10.3389/fgene.2021.774432</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>LIMD2</italic> is a Prognostic and Predictive Marker in Patients With Esophageal Cancer Based on a ceRNA Network Analysis</article-title>
<alt-title alt-title-type="left-running-head">Chen et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">
<italic>LIMD2</italic> in Esophageal Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Yuanmei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Xinyi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Kunshou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Changkun</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Haiyan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Lin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Zhengrong</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yangfan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weng</surname>
<given-names>Guibin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xiao</surname>
<given-names>Tianya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Junqiang</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1054149/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xu</surname>
<given-names>Yuanji</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1344831/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Thoracic Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Fujian Normal University Qishan Campus, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Integrative Traditional Chinese and Western Medicine, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/23967/overview">Graziano Pesole</ext-link>, University of Bari Aldo Moro, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1236560/overview">YM Tsui</ext-link>, The University of Hong Kong, Hong Kong SAR, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1248726/overview">Maria La Mantia</ext-link>, University of Palermo, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yuanji Xu, <email>xuyuanji@fjmu.edu.cn</email>; Junqiang Chen, <email>junqiangc@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to RNA, a section of the journal Frontiers in Genetics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>774432</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Chen, Huang, Zhu, Li, Peng, Chen, Huang, Zhang, Weng, Xiao, Chen and Xu.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Chen, Huang, Zhu, Li, Peng, Chen, Huang, Zhang, Weng, Xiao, Chen and Xu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Globally, esophageal cancer (ECA) is the seventh most common cancer and sixth most common cause of cancer-associated mortality. However, there are no reliable prognostic and predictive molecular markers for ECA; in addition, the pathogenesis of ECA is not fully elucidated. The expressions of circular RNAs (circRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) of ECA and control groups were obtained from the RNA-sequencing (RNA-seq) data of our hospital, the Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA) datasets. Analyses of differentially expressed genes, the circRNA&#x2013;miRNA&#x2013;mRNA&#x2013;competing endogenous RNA (ceRNA) network, and functional/pathway enrichment were conducted. The key targets in the ceRNA network that showed significant results in survival Cox regression analyses were selected. Furthermore, analyses of immune infiltration and autophagy genes related to the key targets were performed. Seven circRNAs, 22 miRNAs, and 34 mRNAs were identified as vital genes in ECA; the nuclear factor-&#x3ba;-gene binding (NF-&#x3ba;B) and phosphatidylinositol-3 kinase/protein kinase B (PI3K-Akt) signaling were identified as the most enriched pathways. In addition, the LIM domain containing 2 (<italic>LIMD2</italic>) was an independent predictor of prognosis in ECA patients and closely associated with immunity and autophagy. Moreover, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) revealed significant upregulation of <italic>LIMD2</italic> expression in ECA tissues. ECA may be closely correlated with NF-&#x3ba;B and PI3K/Akt signaling. In addition, <italic>LIMD2</italic> could be a potential prognostic and predictive marker of&#x20;ECA.</p>
</abstract>
<kwd-group>
<kwd>esophageal cancer</kwd>
<kwd>competing endogenous RNA</kwd>
<kwd>LIM domain containing</kwd>
<kwd>prognostic</kwd>
<kwd>predictive</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Esophageal cancer (ECA), including esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), is the seventh most common malignant tumor in the world and the sixth most common primary cause of tumor-associated death, especially in Asia (<xref ref-type="bibr" rid="B5">Bray et&#x20;al., 2018</xref>). In 2018, approximately 572,034 new ECA cases were diagnosed (accounting for 3.2% of all cancer-related deaths) and 508,585 deaths were caused by ECA (accounting for 3.3% of all malignancies) (<xref ref-type="bibr" rid="B5">Bray et&#x20;al., 2018</xref>). Surgical removal of tumors is the conventional treatment for most types of ECA. Although advances in surgical procedures, chemoradiotherapy, and immunotherapy have helped improve the overall survival (OS) of patients, the current 5-year survival rates of ECA patients still range from 15 to 25% (<xref ref-type="bibr" rid="B25">Pennathur et&#x20;al., 2013</xref>). Therefore, in-depth exploration of potential prognostic and predictive markers, therapeutic targets, and mechanisms of ECA is a key imperative to improve the treatment outcomes and prognosis of ECA patients.</p>
<p>Due to the rapid advances in microarray and RNA-sequencing (RNA-seq) technology, multiple circular RNAs (circRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) have been identified as important genes in ECA (<xref ref-type="bibr" rid="B31">Ritchie et&#x20;al., 2015</xref>). CircRNAs are endogenous non-coding&#x20;RNAs with closed-loop structures without 5&#x2032;caps and&#x20;3&#x2032; tails (<xref ref-type="bibr" rid="B17">Kristensen et&#x20;al., 2019</xref>). Recent studies have found that the mRNAs targeted by miRNAs in the circRNA&#x2013;miRNA&#x2013;mRNA&#x2013;competing endogenous RNA (ceRNA) regulatory network could serve as a key therapeutic target in cancer. In addition, circRNAs were shown to play a vital role in the occurrence and development of cancers by positively or negatively regulating the circRNA&#x2013;miRNA&#x2013;mRNA&#x2013;ceRNA axis or by acting as protein &#x201c;sponges&#x201d; in cancer cells. CircRNAs in the ceRNA network may indirectly regulate those target mRNAs by serving as miRNA &#x201c;sponges&#x201d; (<xref ref-type="bibr" rid="B46">Zhang et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B38">Wu et&#x20;al., 2019</xref>). In a study, low expression of large tumor suppressor kinase 1 (<italic>LATS1</italic>) was found to be related to the tumor stage and poor prognosis of gastric cancer patients; in addition, circ<italic>LARP4</italic> was found to inhibit the malignant biological behavior of gastric cancer as a tumor suppressor <italic>via</italic> the modulation of the circ<italic>LARP4</italic>/miR-424-5p/<italic>LATS1</italic> axis (<xref ref-type="bibr" rid="B41">Yang et&#x20;al., 2018</xref>).</p>
<p>Genome-wide analyses of ECA have indicated complex mutation situations and discovered significant gene mutations (including <italic>TP53, MLL2</italic>, <italic>NOTCH1, and PTEN</italic>), repeated copy number amplifications in <italic>SOX2, TERT, and FGFR1</italic>, as well as frequent deletion of RB1 (<xref ref-type="bibr" rid="B7">Chang et&#x20;al., 2017</xref>; (<xref ref-type="bibr" rid="B11">Cancer Genome Atlas Research Network, 2017</xref>). However, previous ECA genome studies had some limitations, including relatively small sample size, low-coverage whole-genome sequencing, and one-sided analysis based only on chip data or sequencing data. Therefore, more comprehensive studies are required to overcome the shortcomings of previous studies.</p>
<p>The purpose of our study was to explore the potential prognostic and predictive markers and to unravel the mechanisms of ECA from our RNA-seq data, the Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA) database. Differentially expressed circRNAs (DEcircRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) were identified&#x20;using the Limma R package, and the circRNA&#x2013;miRNA&#x2013;mRNA&#x2013;ceRNA regulatory network was constructed based on these differentially expressed genes. In addition, the enriched pathways were investigated by performing multiple functional and pathway enrichment analyses. Furthermore, the key target mRNAs in the ceRNA regulatory network were determined using survival Cox regression analyses. Finally, analyses of immune infiltration autophagy genes related to the key targets were performed. Our study may provide novel insights into the prognosis and treatment of ECA based on the pathogenetic mechanism.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Sample Collection</title>
<p>Between July and December 2020, a total of 20 pairs of tumor and adjacent tissues were collected from patients with pathologically confirmed ECA at the Department of Thoracic Surgery, Fujian Cancer Hospital. The Ethics Committee of the Fujian Cancer Hospital approved the use of human tissues (Project Ethics Number: SQ 2020-063-01), and informed consent was acquired. The study protocol conformed to the principles enshrined in the Declaration of Helsinki.</p>
</sec>
<sec id="s2-2">
<title>RNA Sequencing</title>
<p>Six pairs of esophageal cancer and adjacent normal tissues from Fujian Cancer Hospital between July 1st and July 17th, 2020 were used for RNA-sequencing. First, we characterized circRNA transcripts by sequencing analysis of ribosomal RNA and linear RNA. The total RNA was extracted by the Trizol method. Then, every sample was sequenced on Illumina HiSeq yielding an average of 42.38 million reads, which were mapped to the human reference genome (GRCh38/hg38) by TopHat2 (v2.1.1). The CIRC explorer program (v2.2.3) was used with the fusion junctions obtained from TopHat2 to identify both the circularizing junction and the spliced sequence of circRNAs. The whole step of library construction and sequencing was performed at Shanghai Life genes Technology Co. Ltd.</p>
</sec>
<sec id="s2-3">
<title>Datasets</title>
<p>The chip data of circRNA expression profiles, that is, GSE131969 (GPL 19978) were downloaded from the GEO (<xref ref-type="bibr" rid="B3">Barrett et&#x20;al., 2013</xref>). The miRNA and mRNA expression and clinical information in TCGA were obtained from the University of California Santa Cruz (USCS) Xena. The circRNA microarray data included three ECA tissues and three adjacent normal esophageal tissues. The miRNA sequencing data included 185 ECA samples and 13 adjacent samples, and the mRNA sequencing data included 162 ECA samples and 11 adjacent samples.</p>
</sec>
<sec id="s2-4">
<title>Differential Expression Analyses</title>
<p>The Limma R package (version 4.0.2) (<xref ref-type="bibr" rid="B31">Ritchie et&#x20;al., 2015</xref>) and the edge R package (version 3.14.0) (<xref ref-type="bibr" rid="B32">Robinson et&#x20;al., 2010</xref>) were used for differential analyses. The expressions of all differentially expressed genes (DEGs) were visualized by volcano maps and two-way clustering heat maps. Principal component analysis (PCA) was conducted with the &#x201c;pca3d&#x201d; R package to explore gene expression patterns of ECA and normal groups.</p>
</sec>
<sec id="s2-5">
<title>Construction of the ceRNA and circRNA-RBP Network</title>
<p>MiRanda was used to predict the target miRNAs of the DEcircRNAs. Target mRNAs of DEmiRNAs were predicted using miRWalk (version 2.0) (<xref ref-type="bibr" rid="B10">Dweep, Gretz, 2015</xref>). The databases used for targeted mRNA prediction included miRWalk, Microt4, miRanda, mirbridge, miRDB, miRMap, and Targetscan. Overlapping mRNAs in six or more databases were considered the target mRNAs. Moreover, the ceRNA network was constructed and visualized by Cytoscape (version 3.6.1) (<xref ref-type="bibr" rid="B34">Shannon et&#x20;al., 2003</xref>). The potential RNA binding proteins (RBPs) were analyzed by the CatRAPID database. A star rating score &#x3e; 2 was considered indicative of strong binding effect. Cytoscape software was used to construct the circRNA&#x2013;RBP binding network.</p>
</sec>
<sec id="s2-6">
<title>Functional and Pathway Enrichment Analyses</title>
<p>The mRNAs in the ceRNA network were analyzed using Search Tool for the Retrieval of Interacting Genes (STRING) (<xref ref-type="bibr" rid="B35">Szklarczyk et&#x20;al., 2019</xref>), Database for Annotation, Visualization, and Integrated Discovery (DAVID) (<xref ref-type="bibr" rid="B9">Dennis et&#x20;al., 2003</xref>), and Metascape (<xref ref-type="bibr" rid="B48">Zhou et&#x20;al., 2019</xref>). Metascape, DAVID, and STRING databases were used to conduct analyses based on DisGeNET (version 7.0) (<xref ref-type="bibr" rid="B28">Pi&#xf1;ero et&#x20;al., 2020</xref>), Gene Ontology (GO) (<xref ref-type="bibr" rid="B2">Ashburner et&#x20;al., 2000</xref>), biological processes (BPs), Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining (TRRUST) database (version 2) (<xref ref-type="bibr" rid="B12">Han et&#x20;al., 2018</xref>), and Kyoto Encyclopedia of Genes and Genomes (KEGG) (<xref ref-type="bibr" rid="B16">Kanehisa et&#x20;al., 2017</xref>) analyses.</p>
</sec>
<sec id="s2-7">
<title>Gene Set Variation Analysis</title>
<p>The enrichment scores of pathways were calculated using the GSVA (<xref ref-type="bibr" rid="B13">H&#xe4;nzelmann et&#x20;al., 2013</xref>), and a scoring matrix was obtained. Based on the matrix, the difference analysis was performed using Limma and visualized with a two-way clustering heat&#x20;map.</p>
</sec>
<sec id="s2-8">
<title>Survival Analysis</title>
<p>Based on the optimal cutoff calculated by the survminer R package (<xref ref-type="bibr" rid="B1">Alboukadel et&#x20;al., 2020</xref>), the patients were divided into&#x20;low and high gene expression groups. Between-group differences were evaluated using the log-rank test with the survival (version 3.2-7) R package (<xref ref-type="bibr" rid="B36">Therneau, 2020</xref>), and target genes that showed significant association with survival were&#x20;chosen (<italic>p</italic>&#x20;&#x3c; 0.05). Furthermore, single-factor and multi-factor Cox regression analyses were performed on mRNAs with significant results. Finally, LIM domain containing 2 (<italic>LIMD2</italic>) with significant results was selected as a key target.</p>
</sec>
<sec id="s2-9">
<title>Immune Infiltration Related Analysis</title>
<p>Based on TCGA database, CIBERSORT (<xref ref-type="bibr" rid="B24">Newman et&#x20;al., 2015</xref>) was used to perform immune infiltration&#x2013;related analysis, and immune cells were visualized between groups. Based on the ratio of various immune cells, Spearman&#x2019;s correlation analysis was performed to assess the correlation between immune cells and between targets and immune&#x20;cells.</p>
</sec>
<sec id="s2-10">
<title>Autophagy Correlation Analysis</title>
<p>The autophagy-related genes were obtained from the Human Autophagy Database (HADb). The expressions of key target <italic>LIMD2</italic> and autophagy-related genes were analyzed by Spearman&#x2019;s correlation analysis, and the <italic>p-</italic>values were adjusted using the BH method.</p>
</sec>
<sec id="s2-11">
<title>Gene Set Enrichment Analysis</title>
<p>GSEA (<xref ref-type="bibr" rid="B30">Reimand et&#x20;al., 2019</xref>), performed by R package cluster Profiler (version 3.8.0) (<xref ref-type="bibr" rid="B43">Yu et&#x20;al., 2012</xref>), was used to analyze the significant function and pathway difference between high- and low- <italic>LIMD2</italic> groups. <italic>P-</italic>value &#x3c;0.05 and FDR <italic>q-</italic>value &#x3c; 0.25 were set as the cutoff criteria.</p>
</sec>
<sec id="s2-12">
<title>Single-Factor and Multi-Factor Cox Regression Analyses</title>
<p>Among the clinical variables, age, M stage, N stage, T stage, sex, tumor stage, and <italic>LIMD2</italic> expression were selected for univariate Cox regression analysis. Multivariate Cox regression analyses were conducted using variables that showed significant results in univariate Cox regression analysis.</p>
</sec>
<sec id="s2-14">
<title>qRT-PCR Validation for the Expression of <italic>LIMD2</italic>
</title>
<p>Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied to verify the expression of the target LIMD2 in 20 pairs of ECA and adjacent normal esophageal tissues. The primers of LIMD2 were purchased from BioSune (Shanghai, China) (<xref ref-type="table" rid="T2">Table 2</xref>). An RT2162; All-in-One Mix with dsDNase (Monad Biotech Co. Ltd., Shanghai, China) was used to synthesize cDNA from 1&#x00a0;&#x00b5;g of total RNA. The qRT-PCR analyses were conducted on the Quant Studio 6 Flex qRT-PCR system (Applied Biosystems, Thermo Fisher Scientific Co. Ltd., United States) using the Hieff &#x00ae;qPCR SYBR&#x00ae; Green Master Mix, Low Rox (Yeasen, Biotechnology Co., Ltd, Shanghai, China). The reaction was: 95&#x00b0;C for 10&#x00a0;min, then 40 cycles of 95&#x00b0;C for 15&#x00a0;s and 6&#x00b0;C for 1&#x00a0;min. The reference gene was GAPDH, and the relative gene expression levels were calculated using the 2&#x2212;&#x0394;&#x0394;Ct method.</p>
</sec>
<sec id="s2-13">
<title>Statistical Analysis</title>
<p>Statistical analyses were performed using R software (version 3.6.1), GraphPad Prism (version 8.0.1.244), SPSS (version 24.0), and the bioinformatics tools mentioned above. Differential expressions of genes were obtained by two-tailed Student&#x2019;s t-test. The Benjamini and Hochberg FDR method was conducted to adjust the <italic>p-</italic>values. Enrichment analyses were analyzed using the hypergeometric test and Bonferroni correction. The outcomes were expressed as the mean&#x20;&#xb1; SD and between-group differences were assessed using the paired Student&#x2019;s <italic>t</italic>-test and Wilcoxon rank sum test. <italic>P</italic> values &#x3c; 0.05 were considered indicative of statistical significance.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Data Collection and Preprocessing</title>
<p>The differences between the clustering of the circRNAs (<xref ref-type="fig" rid="F1">Figures 1A,D</xref>), mRNAs (<xref ref-type="fig" rid="F2">Figures 2A,D</xref>), and miRNAs (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>) of the ECA and adjacent samples were analyzed. The results showed that most principal components could separate or tended to separate ECA samples from normal esophageal tissues.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Identification of differentially expressed circRNAs (DEcircRNAs) in esophageal cancer (ECA). <bold>(A, D)</bold> Principal component analysis (PCA) of circRNA expression between ECA and normal groups in GSE131969 and the present RNA-sequencing (RNA-seq) data. <bold>(B, E)</bold> Volcano plot of the distributions of all DEcircRNAs in GSE131969 and the current RNA-seq data. <bold>(C, F)</bold> Hierarchical clustering heatmap of dysregulated circRNAs between ECA and the adjacent normal tissues in GSE131969 and the present RNA-seq data. <bold>(G, H)</bold> Comparison of differentially expressed circRNAs identified in GSE131969 and our RNA-seq data.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Identification of differentially expressed mRNAs (DEmRNAs) in ECA. <bold>(A, D)</bold> PCA of mRNA expression between ECA and normal groups in TCGA cohort and the present RNA-seq data. <bold>(B, E)</bold> Volcano plot of the distributions of all differentially expressed mRNAs in TCGA cohort and the current RNA-seq data. <bold>(C, F)</bold> Hierarchical clustering heatmap of dysregulated mRNAs between ECA and the adjacent normal tissues in TCGA cohort and the present RNA-seq data. <bold>(G, H)</bold> Comparison of differentially expressed mRNAs identified in TCGA cohort and our RNA-seq data.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Identification of differentially expressed miRNAs (DEmiRNAs) in ECA, the ceRNA network, and the circRNA&#x2013;RNA binding protein (RBP) network. <bold>(A)</bold> PCA of miRNA expression between ECA and normal groups in TCGA cohort. <bold>(B)</bold> Volcano plot of the distributions of all DEmiRNAs in TCGA cohort. <bold>(C)</bold> Hierarchical clustering heatmap of dysregulated miRNAs between ECA and the adjacent normal tissues in TCGA cohort. <bold>(D)</bold> CeRNA network of circRNA&#x2013;miRNA&#x2013;mRNA in ECA; <bold>(E)</bold> circRNA&#x2013;RBP binding network.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g003.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Identification of DEcircRNAs, DEmiRNAs, and DEmRNAs</title>
<p>CircRNAs in GSE131969 and RNA-seq data (<italic>p-</italic> value &#x3c;0.05 and &#x7c;log2 FC&#x7c; &#x3e; 1.5), mRNAs in RNA-seq data (<italic>p-</italic> value &#x3c;0.05 and &#x7c;log2 FC&#x7c; &#x3e; 1) and TCGA dataset (<italic>p</italic> value &#x3c;0.05 and &#x7c;log2 FC&#x7c; &#x3e; 1.5), as well as miRNAs inTCGA (<italic>p</italic> value &#x3c;0.05 and &#x7c;log2 FC&#x7c; &#x3e; 1.5) were analyzed. A total of 368 DEcircRNAs were identified in GSE131969 (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), 493 DEcircRNAs were identified in RNA-seq data (<xref ref-type="fig" rid="F1">Figure&#x20;1E</xref>), 1576 DEmRNAs were identified in RNA-seq data (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>), 2450 DEmRNAs were identified in TCGA (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>), and 86 DEmRNAs were identified in TCGA (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>). The DEcircRNAs in the GEO (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>) and RNA-seq data (<xref ref-type="fig" rid="F1">Figure&#x20;1F</xref>) and DEmRNAs in RNA-seq data (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) and TCGA (<xref ref-type="fig" rid="F2">Figure&#x20;2F</xref>), as well as DEmiRNAs in TCGA (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>), were visualized using the hierarchical cluster maps. Seven upregulated circRNAs (<xref ref-type="fig" rid="F1">Figure&#x20;1G</xref>), zero downregulated circRNAs (<xref ref-type="fig" rid="F1">Figure&#x20;1H</xref>) and 61 upregulated mRNAs (<xref ref-type="fig" rid="F2">Figure&#x20;2G</xref>) and six downregulated mRNAs (<xref ref-type="fig" rid="F2">Figure&#x20;2H</xref>) were significantly differentially expressed in both datasets. Finally, seven DEcircRNAs in the GSE131969 (<xref ref-type="sec" rid="s11">Supplementary Figure S1A</xref>) and RNA-seq data (<xref ref-type="sec" rid="s11">Supplementary Figure S1B</xref>) were visualized.</p>
</sec>
<sec id="s3-3">
<title>Construction of the CeRNA Network and CircRNA&#x2013;RBP Network</title>
<p>The miRNAs targeted by the seven DEcircRNAs were predicted and 22 circRNA&#x2013;miRNA pairs were identified. The mRNAs targeting the miRNAs were identified, and 34 mRNAs were obtained through the intersection with DEmRNAs (<xref ref-type="fig" rid="F4">Figure&#x20;4D</xref>). Subsequently, the differential expression of the 34 mRNAs TCGA database (<xref ref-type="sec" rid="s11">Supplementary Figure S3A</xref>) and RNA-seq data were visualized (<xref ref-type="sec" rid="s11">Supplementary Figure S3B</xref>). A ceRNA network was established based on seven circRNAs, 22 miRNAs, and 34 mRNAs (<xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>). The circRNA&#x2013;RBP network was constructed, including seven circRNAs and 37 RBPs (<xref ref-type="fig" rid="F3">Figure&#x20;3E</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Biological enrichment analyses of target mRNAs. <bold>(A)</bold> Enrichment results based on the DisGeNET database. <bold>(B)</bold> Enrichment results based on the gene ontology (GO) and biological process (BP) databases. <bold>(C)</bold> Enrichment results based on the TRRUST database. <bold>(D)</bold> Comparison of target mRNAs predicted by miRNAs and differentially expressed mRNAs. <bold>(E)</bold> GSVA analysis of key targets.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Functional and Pathway Enrichment Analyses</title>
<p>The enriched terms analyzed based on the DisGeNET database are shown in <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>, including adult T-Cell lymphoma and childhood Langerhans cell histiocytosis. The enriched GO terms are shown in <xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>, including positive regulation of cell adhesion and positive regulation of protein kinase B signaling. The enriched terms analyzed based on the TRRUST database were SP1, RELA, and NFKB1 (<xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>). Moreover, GSVA showed enrichment of ether lipid metabolism or acute myeloid leukemia in the cancer group (<xref ref-type="fig" rid="F4">Figure&#x20;4E</xref>). Based on the DAVID database, the outcomes showed that mRNAs were enriched in positive regulation of T&#x20;cell activation and cell migration (BP), extracellular space, plasma membrane (cellular components, CCs), DNA binding (Molecular Functions, MFs), and NF-kappa B signaling pathway (KEGG, <xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref>). Based on the STRING database, the results showed that targets were enriched in positive regulation of lymphocyte activation and immune system process (BPs), extracellular space (CC), protein binding and DNA binding (MFs), NF-kappa B pathway and ether lipid metabolism (KEGG), and regulation of PI3K/AKT signaling (record control the memory, RCTM, <xref ref-type="sec" rid="s11">Supplementary Figure&#x20;S2B</xref>).</p>
</sec>
<sec id="s3-5">
<title>Survival Analysis</title>
<p>Targets that showed a significant association with survival (<italic>p</italic>&#x20;&#x3c; 0.05) included <italic>LIMD2</italic>, <italic>ARL11, and SERPINB7</italic> (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;L</xref>). <italic>LIMD2</italic> with significant regression results was selected as a key target.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effect of target mRNA expression on the OS of ECA patients in TCGA database. Kaplan&#x2013;Meier (KM) curves demonstrating the distinct outcomes of ECA patients. <bold>(A&#x2013;L)</bold> KM curve of <italic>LIMD2</italic> <bold>(A)</bold>, <italic>ARL11</italic> <bold>(B)</bold>, <italic>CARD11</italic> <bold>(C)</bold>, <italic>ENKUR</italic> <bold>(D)</bold>, <italic>HS3ST3A1</italic> <bold>(E)</bold>, <italic>KIT</italic> <bold>(F)</bold>, <italic>LCK</italic> <bold>(G)</bold>, <italic>LPCAT1</italic> <bold>(H)</bold>, <italic>NABP1</italic> <bold>(I)</bold>, <italic>NRXN1</italic> <bold>(J)</bold>, <italic>PPP1R18</italic> <bold>(K)</bold>, and <italic>SERPINB7</italic> <bold>(L)</bold>.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Immune Infiltration Analysis</title>
<p>The composition of immune cells in the tumor microenvironment (TME) in the ECA and normal groups was analyzed. We observed significant differences in TME cell infiltration and composition in the two groups, including memory activated CD4 T&#x20;cells and M1 macrophages (<xref ref-type="fig" rid="F6">Figure&#x20;6A</xref>). The <italic>R</italic>
<sup>2</sup> of TME cells was also calculated, and the results showed that memory activated CD4 T&#x20;cells had statistical significance (<xref ref-type="fig" rid="F6">Figure&#x20;6B</xref>). A positive relationship was observed between <italic>LIMD2</italic> and memory activated CD4 T&#x20;cells (<xref ref-type="fig" rid="F6">Figure&#x20;6C</xref>). These analyses indicated a positive correlation of the ECA group with immune-relevant signatures.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Immune infiltration correlation analysis in ECA based on TCGA cohort. <bold>(A)</bold> Fraction of the immune tumor microenvironment (TME) cells in the ECA and normal groups, and TME cells between the ECA and normal groups are analyzed in the figure given below. Within each group, the scattered dots represent the expression values of TME cells. The bottom and top of the boxes are the 25th and 75th percentiles (interquartile range). The whiskers encompass 1.5&#x20;times the interquartile range. <bold>(B)</bold> Immune infiltration correlation analysis; <bold>(C)</bold> Plots showing Spearman&#x2019;s correlation of <italic>LIMD2</italic> and memory activated CD4 T&#x20;cells.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g006.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>Analysis of <italic>LIMD2</italic> and Autophagy-Related Genes</title>
<p>Several studies have indicated the importance of autophagy in the development of ECA (<xref ref-type="bibr" rid="B8">Chen et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B18">Li et&#x20;al., 2020</xref>). We investigated the relationship between <italic>LIMD2</italic> and autophagy-related genes (<xref ref-type="fig" rid="F7">Figures 7A&#x2013;I</xref>). The top nine autophagy-related genes that showed a positive relationship with <italic>LIMD2</italic> were identified, including <italic>BCL-2</italic>, <italic>CCL2</italic>, <italic>RGS19, DRAM1</italic>, <italic>GRID1</italic>, <italic>NLRC4</italic>, <italic>PELP1</italic>, <italic>PRKCQ</italic>, and <italic>RGS19</italic>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Plots showing Spearman&#x2019;s correlation of <italic>LIMD2</italic> and autophagy-related genes in TCGA cohort. In every plot, the X-axis represents <italic>LIMD2</italic> and the Y-axis represents autophagy-related genes. <bold>(A&#x2013;I)</bold> Spearman&#x2019;s correlation of <italic>LIMD2</italic> and <italic>BCL-2</italic> <bold>(A)</bold>, <italic>CCL2</italic> <bold>(B)</bold>, <italic>CXCR4</italic> <bold>(C)</bold>, <italic>DRAM1</italic> <bold>(D)</bold>, <italic>GRID1</italic> <bold>(E)</bold>, <italic>NLRC4</italic> <bold>(F)</bold>, <italic>PELP1</italic> <bold>(G)</bold>, <italic>PRKCQ</italic> <bold>(H)</bold>, and <italic>RGS19</italic> <bold>(I)</bold>. Dashed line in each plot is the regression&#x20;line.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g007.tif"/>
</fig>
</sec>
<sec id="s3-8">
<title>GSEA</title>
<p>The results demonstrated that the ECA patients with high expression of <italic>LIMD2</italic> showed enrichment of the following pathways: systemic lupus erythematosus, DNA replication, and T&#x20;cell receptor signaling pathway (<xref ref-type="sec" rid="s11">Supplementary Figures S4A&#x2013;I</xref>).</p>
</sec>
<sec id="s3-9">
<title>Cox Regression Analysis</title>
<p>Univariate and multivariate Cox regression analyses were performed to explore independent predictors of survival in ECA patients. A total of 162 ECA patients were included in the regression analysis. In univariate Cox regression analysis, <italic>LIMD2</italic>, M stage, N stage, and tumor stage showed a strong association with OS. Based on the results of univariate Cox analysis, multivariate Cox regression analysis was performed to analyze the effect of <italic>LIMD2</italic> and other related clinical phenotypes on the prognosis of ECA. In multivariate Cox regression analysis, <italic>LIMD2</italic> showed a significant correlation with OS (<xref ref-type="table" rid="T1">Table&#x20;1</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>). The results showed that <italic>LIMD2</italic> is an independent predictor of OS in ECA patients.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Results of univariate analysis and multivariate analysis showing prognostic factors for OS.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">Variables</th>
<th colspan="3" align="center">Univariate analysis</th>
<th colspan="3" align="center">Multivariate analysis</th>
</tr>
<tr>
<th align="center">HR</th>
<th align="center">95% CI</th>
<th align="center">
<italic>p</italic> Value</th>
<th align="center">HR</th>
<th align="center">95% CI</th>
<th align="center">
<italic>p</italic> Value</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="7" align="left">Age</td>
</tr>
<tr>
<td align="left">&#x2003;&#x2265;60 (77/137)</td>
<td align="center">0.9911</td>
<td align="center">0.574&#x2013;1.711</td>
<td align="center">0.974</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">Tumor_central location</td>
</tr>
<tr>
<td align="left">&#x2003;Mid (36/142)</td>
<td align="center">8.6e-01</td>
<td align="center">0.391&#x2013;1.893</td>
<td align="center">0.709</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x2003;Proximal (6/142)</td>
<td align="center">3.75e-08</td>
<td align="center">0-Inf</td>
<td align="center">0.997</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">M stage</td>
</tr>
<tr>
<td align="left">&#x2003;M1 (8/143)</td>
<td align="center">5.32</td>
<td align="center">2.449&#x2013;11.576</td>
<td align="center">2.45e-05</td>
<td align="center">2.149</td>
<td align="center">0.9242&#x2013;4.997</td>
<td align="center">0.0756</td>
</tr>
<tr>
<td colspan="7" align="left">N stage</td>
</tr>
<tr>
<td align="left">&#x2003;N1-N3 (77/143)</td>
<td align="center">3.504</td>
<td align="center">1.82&#x2013;6.744</td>
<td align="center">0.000175</td>
<td align="center">2.088</td>
<td align="center">0.946&#x2013;4.611</td>
<td align="center">0.0685</td>
</tr>
<tr>
<td colspan="7" align="left">T stage</td>
</tr>
<tr>
<td align="left">&#x2003;T3-T4 (80/143)</td>
<td align="center">1.2498</td>
<td align="center">0.719&#x2013;2.173</td>
<td align="center">0.43</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">Gender</td>
</tr>
<tr>
<td align="left">&#x2003;Male (121/143)</td>
<td align="center">2.366</td>
<td align="center">0.852&#x2013;6.572</td>
<td align="center">0.0984</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">Tumor stage</td>
</tr>
<tr>
<td align="left">&#x2003;Stage iii-stage iv (58/143)</td>
<td align="center">3.398</td>
<td align="center">1.9&#x2013;6.076</td>
<td align="center">3.68e-05</td>
<td align="center">2.078</td>
<td align="center">0.98&#x2013;4.406</td>
<td align="center">0.0564</td>
</tr>
<tr>
<td colspan="7" align="left">Alcohol history</td>
</tr>
<tr>
<td align="left">&#x2003;Yes (97/140)</td>
<td align="center">0.674</td>
<td align="center">0.386&#x2013;1.177</td>
<td align="center">0.166</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">Smoking history</td>
</tr>
<tr>
<td align="left">&#x2003;2 (30/125)</td>
<td align="center">1.65699</td>
<td align="center">0.6496&#x2013;4.226</td>
<td align="center">0.2905</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x2003;3 (28/125)</td>
<td align="center">0.96495</td>
<td align="center">0.3601&#x2013;2.585</td>
<td align="center">0.9434</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x2003;4 (26/125)</td>
<td align="center">2.38885</td>
<td align="center">0.9319&#x2013;6.123</td>
<td align="center">0.0698</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">BMI</td>
</tr>
<tr>
<td align="left">&#x2003;&#x3e;30 (15/134)</td>
<td align="center">0.3895</td>
<td align="center">0.122&#x2013;1.244</td>
<td align="center">0.1116</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x2003;25-30 (72/134)</td>
<td align="center">0.462</td>
<td align="center">0.1757&#x2013;1.216</td>
<td align="center">0.1177</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td align="left">&#x2003;18.5-25 (39/134)</td>
<td align="center">0.456</td>
<td align="center">0.181&#x2013;1.152</td>
<td align="center">0.0968</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
<td align="center">&#x2014;</td>
</tr>
<tr>
<td colspan="7" align="left">
<italic>LIMD2</italic>
</td>
</tr>
<tr>
<td align="left">&#x2003;Low (94/143)</td>
<td align="center">2.9065</td>
<td align="center">1.413&#x2013;5.981</td>
<td align="center">0.00375</td>
<td align="center">2.629</td>
<td align="center">1.2486&#x2013;5.537</td>
<td align="center">0.0109</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>HR, hazard ratio; CI, confidence interval; Smoking history: 1, lifelong non-smoker (less than 100 cigarettes smoked in lifetime); 2, current smoker (includes daily smokers and non-daily smokers or occasional smokers); 3, current reformed smoker for more than15&#xa0;years (greater than 15&#xa0;years); 4, current reformed smoker for &#x2264;15&#xa0;years (less than or equal to 15&#xa0;years).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-10">
<title>Validation of <italic>LIMD2</italic> by QRT-PCR</title>
<p>To verify the RNA-seq and bioinformatics results, the target <italic>LIMD2</italic> was chosen for validation by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) with primers (<xref ref-type="table" rid="T2">Table&#x20;2</xref>). The results showed significantly higher expression of <italic>LIMD2</italic> in ECA tissues compared with that of normal tissues (<xref ref-type="fig" rid="F8">Figure&#x20;8</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Primers for <italic>LIMD2</italic> and <italic>GAPDH</italic>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Primers</th>
<th align="center">Forward primers (5&#x2032;to 3&#x2032;)</th>
<th align="center">Reverse primers (5&#x2032;to 3&#x2032;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">qPCR-<italic>LIMD2</italic>
</td>
<td align="left">TTT&#x200b;TCC&#x200b;ACA&#x200b;ACT&#x200b;CTT&#x200b;GCT&#x200b;TCT&#x200b;GC</td>
<td align="left">AAC&#x200b;CCC&#x200b;TCG&#x200b;TCG&#x200b;TAG&#x200b;TTG&#x200b;CCT</td>
</tr>
<tr>
<td align="left">qPCR-<italic>GAPDH</italic>
</td>
<td align="left">GGA&#x200b;GCG&#x200b;AGA&#x200b;TCC&#x200b;CTC&#x200b;CAA&#x200b;AAT</td>
<td align="left">GGC&#x200b;TGT&#x200b;TGT&#x200b;CAT&#x200b;ACT&#x200b;TCT&#x200b;CAT&#x200b;GG</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Validation of the expression of target <italic>LIMD2</italic>. The <italic>LIMD2</italic> expression in ECA (<italic>n</italic>&#x20;&#x3d; 20) and adjacent normal tissues (<italic>n</italic>&#x20;&#x3d; 20) was evaluated by qRT-PCR; the results were analyzed using the paired sample <italic>t-</italic>test <bold>(A)</bold> and Wilcoxon rank sum test <bold>(B)</bold>. Results expressed as mean&#x20;&#xb1; standard deviation (SD). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 and &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fgene-12-774432-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this study, seven circRNAs, 22 miRNAs, and 34 target mRNAs in the circRNA&#x2013;miRNA&#x2013;mRNA&#x2013;ceRNA regulatory network were identified as crucial genes in ECA; in addition, the nuclear factor-k-gene binding (NF-&#x3ba;B) and phosphatidylinositol-3 kinase/protein kinase B (PI3K-Akt) signaling were identified as the most enriched pathways. Survival Cox regression analyses indicated that the target <italic>LIMD2</italic> in the ceRNA network may act as an independent predictor of OS in ECA patients. On further analyses of immune infiltration and autophagy genes related to target <italic>LIMD2</italic>, <italic>LIMD2</italic> showed a close linkage with immunity and autophagy in ECA. Furthermore, we verified the high expression level of <italic>LIMD2</italic> by qRT-PCR based on 20 pairs of ECA and normal samples. Hence, <italic>LIMD2</italic> is a potential molecular marker of prognostic and predictive significance in&#x20;ECA.</p>
<p>The ceRNA networks may play a vital role in the development of cancer (<xref ref-type="bibr" rid="B20">Liu et&#x20;al., 2021</xref>). Seven circRNAs, 22 miRNAs, and 34 mRNAs were identified in the ceRNA network. The increase of has_circ_0000154 (circDCAF6) identified in our study was related to tumor invasion, positive lymph node metastasis, and a higher TNM stage in GC patients. It could serve as an independent prognostic indicator (<xref ref-type="bibr" rid="B40">Wu et&#x20;al., 2019</xref>). A total of 12 identified mRNAs (<italic>HMGA2, CCL22, CDKN2D, CEACAM6, DKK2, KIT, KRT14, LEF1, LPCAT1, NCCRP1, NRXN1, and PPP1R18</italic>) were found to be related to ECA. In a previous study, high-mobility group AT-hook 2 (<italic>HMGA2</italic>) was shown to regulate transcription by inducing structural alterations in the chromatin (<xref ref-type="bibr" rid="B22">Mansoori et&#x20;al., 2021</xref>). Several studies have shown that <italic>HMGA2</italic> is re-expressed in most tumors and plays a vital role in tumorigenesis (<xref ref-type="bibr" rid="B21">Lu et&#x20;al., 2021</xref>). The stability of <italic>HMGA2</italic> may be regulated by hepatitis B X-interacting protein (<italic>HBXIP</italic>) <italic>via</italic> the Akt-PCAF pathway, thereby promoting the growth of ECA cells (<xref ref-type="bibr" rid="B39">Wu et&#x20;al., 2020</xref>). All 22 DEmiRNAs in the ceRNA network have been reported to be related to cancer. MiR-141-3p plays an important role in various carcinomas (<xref ref-type="bibr" rid="B14">Huang et&#x20;al., 2017</xref>), and it was found to be highly upregulated in ECA cells (<xref ref-type="bibr" rid="B26">Phatak et&#x20;al., 2021</xref>). A recent study reported that miR-141-3p may inhibit the expression of pleckstrin homology domain leucine-rich repeat protein phosphatase-2 (<italic>PHLPP2</italic>), a negative regulator of the PI3K/AKT signaling, and could serve as an biomarker in ECA (<xref ref-type="bibr" rid="B15">Ishibashi et&#x20;al., 2018</xref>).</p>
<p>CircRNAs with RBP binding sites can act as sponges for RBPs and may indirectly modulate their functions (<xref ref-type="bibr" rid="B46">Zhang et&#x20;al., 2017</xref>). In this study, the six identified RBPs (<italic>SRSF1, SRSF2, PCBP2, TIA1, FUS, and FMR1</italic>) were closely related to ECA. <italic>PCBP2</italic> performs multiple functions, such as stabilization of mRNAs and silencing or promotion of translation (<xref ref-type="bibr" rid="B42">Ye et&#x20;al., 2016</xref>). Several studies have shown that <italic>PCBP2</italic> may promote tumor growth. Ye et&#x20;al. found that <italic>PCBP2</italic> regulates the proliferation and apoptosis of ESCC cells and may serve as a novel therapeutic target in ESCC (<xref ref-type="bibr" rid="B42">Ye et&#x20;al., 2016</xref>). Our findings are consistent with those of the previous&#x20;study.</p>
<p>In our study, multiple diseases were enriched in ECA, including adult T&#x20;cell lymphoma (ATL), childhood Langerhans cell histiocytosis, and classical Hodgkin&#x2019;s lymphoma that are strongly associated with immune cells. ATL is a T&#x20;cell lymphoproliferative tumor of mature CD4<sup>&#x2b;</sup> CD25&#x20;<sup>&#x2b;</sup> T&#x20;cells (<xref ref-type="bibr" rid="B23">Mehta-Shah et&#x20;al., 2017</xref>), and Langerhans cell histiocytosis is characterized by the accumulation of Langerhans cells and antigen-presenting cells (<xref ref-type="bibr" rid="B29">Rayamajhi et&#x20;al., 2020</xref>). Our results also revealed a close relation of many enriched GO and KEGG terms with immune response, including positive regulation of T&#x20;cell activation and immune system process. GSEA showed that immunity was strongly associated with ECA, including systemic lupus erythematosus and the T&#x20;cell receptor signaling pathway. The NF-&#x3ba;B signaling and PI3K/AKT signaling pathways were the most enriched pathways. Zheng et&#x20;al. depicted the entire immune landscape, including the innate and acquired immune cell map, in ESCC and adjacent tissues; their work revealed that ESCC is enriched in immune-suppressive cell mass (<xref ref-type="bibr" rid="B47">Zheng et&#x20;al., 2020</xref>). Tong et&#x20;al. revealed that 14-3-3&#x3b6; may enhance the invasion and growth of ESCC cells by inhibiting the <italic>S1PR2</italic> protein expression <italic>via</italic> the NF-&#x3ba;B pathway (<xref ref-type="bibr" rid="B37">Tong et&#x20;al., 2018</xref>). GSVA indicated enrichment of ether lipid metabolism in ECA. Disorders of ether lipid metabolism are vital signs of tumors, which serve as the basis of tumor pathogenicity (<xref ref-type="bibr" rid="B27">Piano et&#x20;al., 2015</xref>). Cao et&#x20;al. found that lncRNAs may interact with their adjacent coding RNAs to modulate ether lipid metabolism (<xref ref-type="bibr" rid="B6">Cao et&#x20;al., 2013</xref>).</p>
<p>Furthermore, we found that 12 genes were strongly related to OS. We included these 12 mRNAs in Cox regression analyses and identified <italic>LIMD2</italic> as a vital prognostic factor. In our study, high expression of <italic>LIMD2</italic> was associated with better OS in ECA. However, Zhang et&#x20;al. found that high expression of <italic>LIMD2</italic> may enhance the progression of non&#x2013;small cell lung carcinoma (NSCLC); in addition, the overexpression of <italic>LIMD2</italic> was closely related to lymph node metastasis, distant metastasis, and advanced stage. The survival time of NSCLC patients with the overexpression of <italic>LIMD2</italic> was shorter than that of patients with lower expression, indicating that <italic>LIMD2</italic> may serve as a therapeutic target in NSCLC (<xref ref-type="bibr" rid="B45">Zhang et&#x20;al., 2019</xref>). Our study indicated that <italic>LIMD2</italic> may serve as an independent predictor of prognosis in ECA patients. In the TME cell composition analysis, Yu et&#x20;al. found that the high-immunity group of cutaneous melanoma specimens had the highest level of memory activated CD4 T&#x20;cells, and the OS rate was poor (<xref ref-type="bibr" rid="B44">Yu et&#x20;al., 2020</xref>). A recent research unraveled the connection between clinical information and immune signatures in GC. They noticed that the high-risk group showed greater proportion of memory activated CD4 T&#x20;cells and M1 macrophages (<xref ref-type="bibr" rid="B19">Liu et&#x20;al., 2020</xref>). Our study has also demonstrated positive relationship of <italic>LIMD2</italic> with nine autophagy-related genes. In our study, <italic>BCL-2</italic>, an autophagy-related gene showed a positive relationship with <italic>LIMD2</italic>, and <italic>BCL-2</italic>&#x2013;associated athanogene 3 (<italic>BAG3</italic>) was shown to be involved in multiple biological processes, including cell proliferation, cell vitality, and apoptosis (<xref ref-type="bibr" rid="B33">Rosati et&#x20;al., 2011</xref>). Compared with Barrett&#x2019;s metaplasia (BE) and normal samples, the amount of T lymphocytes with downregulation of <italic>BCL-2</italic> was notably increased in EAC (<xref ref-type="bibr" rid="B4">Berndt et&#x20;al., 2010</xref>). In short, <italic>LIMD2</italic> is a potential marker of prognostic and predictive significance in&#x20;ECA.</p>
<p>Nevertheless, some limitations of our study should be considered while interpreting the results. First, owing to the use of several datasets in our analyses, the effect of inter-batch differences on our results cannot be ruled out. In addition, further studies with a larger sample size are required to verify the high expression of <italic>LIMD2</italic> in ECA. Moreover, the sample size of squamous carcinoma and adenocarcinoma was too small to be analyzed separately. To avoid unreliable results, we analyzed both histological subtypes. We will further expand the sample size to explore the differences between different subtypes. Finally, further <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> biological experiments on immunity and autophagy are required for in-depth characterization of the functions of the identified targets and potential mechanisms in&#x20;ECA.</p>
<p>In conclusion, we identified seven circRNAs, 22 miRNAs, and 34 mRNAs in the ceRNA network in ECA. The NF-&#x3ba;B and PI3K/Akt signaling pathways were the most enriched pathways in ECA. Furthermore, <italic>LIMD2</italic> was notably upregulated in ECA tissue samples and may serve as a potential prognostic and predictive marker that is closely associated with immunity and autophagy. Our study provides insights into the pathogenesis, prognosis, and therapeutic strategy for&#x20;ECA.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The datasets generated and analyzed for this study can be found in the National Center for Biotechnology Information Gene Expression Omnibus (<xref ref-type="bibr" rid="B3">Barrett et al., 2013</xref>) repository under the accession number GSE131969.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and&#x20;approved by the Ethics Committee of the Fujian Cancer&#x20;Hospital approved the use of human tissues (Project Ethics Number: K2021-027-01). The patients/participants provided their written informed consent to participate in this&#x20;study.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>YC and YX conceived and designed the whole project. YC and XH drafted the manuscript. XH and KZ analyzed the data and prepared figures. XH and CL performed the analyses. HP and LC computed the tables. ZH and YZ collected the data. GW, TX, and JC provided specialized expertise. YX designed the whole project and revised the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported in part by grants from Fujian Provincial Health Technology Project, China (&#x0023;2020GGA017), the Natural Science Foundation of Fujian Province, China (&#x0023;2021J01428, &#x0023;2020J011123), and China Association of Gerontology and Geriatrics (&#x0023;2021-CSGOR-1), Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (2020Y2012), and the National Clinical Key Specialty Construction Program.</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We would like to thank Medjaden Bioscience Limited (MJD) for the paper revision support.</p>
</ack>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2021.774432/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2021.774432/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Alboukadel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marcin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Przemyslaw</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Scheipl</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Survminer: Drawing Survival Curves Using &#x27;ggplot2&#x27;</article-title>. <comment>R package version 0.4.8 Available at:<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survminer/">https://CRAN.R-project.org/package&#x3d;survminer/</ext-link> (Accessed March 20, 2021)</comment>. </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashburner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Botstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cherry</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Gene Ontology: Tool for the Unification of Biology</article-title>. <source>Nat. Genet.</source> <volume>25</volume>, <fpage>25</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/75556</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wilhite</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Ledoux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I. F.</given-names>
</name>
<name>
<surname>Tomashevsky</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>NCBI GEO: Archive for Functional Genomics Data Sets-Update</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume>, <fpage>D991</fpage>&#x2013;<lpage>D995</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berndt</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Philipsen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>R&#xf6;cken</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bertram</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Comparative Multi-Epitope-Ligand-Cartography Reveals Essential Immunological Alterations in Barrett&#x27;s Metaplasia and Esophageal Adenocarcinoma</article-title>. <source>Mol. Cancer</source> <volume>9</volume>, <fpage>177</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-9-177</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA: A Cancer J.&#x20;Clinicians</source> <volume>68</volume>, <fpage>394</fpage>&#x2013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Integrated Analysis of Long Noncoding RNA and Coding RNA Expression in Esophageal Squamous Cell Carcinoma</article-title>. <source>Int. J.&#x20;Genomics</source> <volume>2013</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2013/480534</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<collab>Cancer Genome Atlas Research Network</collab> (<year>2017</year>). <article-title>Integrated Genomic Characterization of Oesophageal Carcinoma</article-title>. <source>Nature</source> <volume>541</volume>, <fpage>169</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/nature20805</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Genomic Analysis of Oesophageal Squamous-Cell Carcinoma Identifies Alcohol Drinking-Related Mutation Signature and Genomic Alterations</article-title>. <source>Nat. Commun.</source> <volume>8</volume>, <fpage>15290</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms15290</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Prognostic Significance of Autophagy-Related Genes within Esophageal Carcinoma</article-title>. <source>BMC Cancer</source> <volume>20</volume>, <fpage>797</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-020-07303-4</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dennis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Hosack</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>H. C.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>DAVID: Database for Annotation, Visualization, and Integrated Discovery</article-title>. <source>Genome Biol.</source> <volume>4</volume>, <fpage>P3</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2003-4-5-p3</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dweep</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gretz</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>MiRWalk2.0: a Comprehensive Atlas of microRNA-Target Interactions</article-title>. <source>Nat. Methods</source> <volume>12</volume>, <fpage>697</fpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3485</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>TRRUST V2: an Expanded Reference Database of Human and Mouse Transcriptional Regulatory Interactions</article-title>. <source>Nucleic Acids Res.</source> <volume>46</volume>, <fpage>D380</fpage>&#x2013;<lpage>D386</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1013</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xe4;nzelmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Castelo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Guinney</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data</article-title>. <source>BMC Bioinformatics</source> <volume>14</volume>, <fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wa</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Downregulation of miR-141-3p Promotes Bone Metastasis via Activating NF-&#x39a;b Signaling in Prostate Cancer</article-title>. <source>J.&#x20;Exp. Clin. Cancer Res.</source> <volume>36</volume>, <fpage>173</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-017-0645-7</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishibashi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Akagi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>MiR-141-3p Is Upregulated in Esophageal Squamous Cell Carcinoma and Targets Pleckstrin Homology Domain Leucine-Rich Repeat Protein Phosphatase-2, a Negative Regulator of the PI3K/AKT Pathway</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>501</volume>, <fpage>507</fpage>&#x2013;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.05.025</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Furumichi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Morishima</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>KEGG: New Perspectives on Genomes, Pathways, Diseases and Drugs</article-title>. <source>Nucleic Acids Res.</source> <volume>45</volume>, <fpage>D353</fpage>&#x2013;<lpage>D361</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kristensen</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Stagsted</surname>
<given-names>L. V. W.</given-names>
</name>
<name>
<surname>Ebbesen</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Kjems</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Biogenesis, Biology and Characterization of Circular RNAs</article-title>. <source>Nat. Rev. Genet.</source> <volume>20</volume>, <fpage>675</fpage>&#x2013;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-019-0158-7</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Identification of Autophagy-Related Genes and Small-Molecule Drugs in Esophageal Carcinoma</article-title>. <source>Med. Sci. Monit.</source> <volume>26</volume>, <fpage>e921855</fpage>. <pub-id pub-id-type="doi">10.12659/MSM.921855</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Comprehensive Analysis of a 14&#x20;Immune-Related Gene Pair Signature to Predict the Prognosis and Immune Features of Gastric Cancer</article-title>. <source>Int. Immunopharmacology</source> <volume>89</volume>, <fpage>107074</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107074</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.-F.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P.-Y.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>R.-Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cancer-associated Fibroblast-Derived CXCL11 Modulates Hepatocellular Carcinoma Cell Migration and Tumor Metastasis through the circUBAP2/miR-4756/IFIT1/3 axis</article-title>. <source>Cell Death Dis</source> <volume>12</volume>, <fpage>260</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-03545-7</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Long Non-coding RNA DANCR Accelerates Colorectal Cancer Progression via Regulating the miR-185-5p/HMGA2 axis</article-title>. <source>J.&#x20;Biochem.</source> <fpage>mvab011</fpage>, <comment>undefined, undefined.</comment> <pub-id pub-id-type="doi">10.1093/jb/mvab011</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansoori</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ditzel</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Duijf</surname>
<given-names>P. H. G.</given-names>
</name>
<name>
<surname>Khaze</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gjerstorff</surname>
<given-names>M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>HMGA2 as a Critical Regulator in Cancer Development</article-title>. <source>Genes</source> <volume>12</volume>, <fpage>269</fpage>. <comment>undefined</comment>. <pub-id pub-id-type="doi">10.3390/genes12020269</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehta-Shah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Adult T-Cell Leukemia/Lymphoma</article-title>. <source>Jop</source> <volume>13</volume>, <fpage>487</fpage>&#x2013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1200/JOP.2017.021907</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Gentles</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Robust Enumeration of Cell Subsets from Tissue Expression Profiles</article-title>. <source>Nat. Methods</source> <volume>12</volume>, <fpage>453</fpage>&#x2013;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pennathur</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Jobe</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Luketich</surname>
<given-names>J.&#x20;D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Oesophageal Carcinoma</article-title>. <source>The Lancet</source> <volume>381</volume>, <fpage>400</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60643-6</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phatak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Noe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asrani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chesnick</surname>
<given-names>I. E.</given-names>
</name>
<name>
<surname>Greenwald</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Donahue</surname>
<given-names>J.&#x20;M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MicroRNA&#x2010;141&#x2010;3p Regulates Cellular Proliferation, Migration, and Invasion in Esophageal Cancer by Targeting Tuberous Sclerosis Complex 1</article-title>. <source>Mol. Carcinogenesis</source> <volume>60</volume>, <fpage>125</fpage>&#x2013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1002/mc.23274</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>D. I.</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nenci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marrocco</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-cancer Agents</article-title>. <source>ACS Chem. Biol.</source> <volume>10</volume>, <fpage>2589</fpage>&#x2013;<lpage>2597</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b00466</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pi&#xf1;ero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ram&#xed;rez-Anguita</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Sa&#xfc;ch-Pitarch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ronzano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Centeno</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The DisGeNET Knowledge Platform for Disease Genomics: 2019 Update</article-title>. <source>Nucleic Acids Res.</source> <volume>48</volume>, <fpage>D845</fpage>&#x2013;<lpage>D855</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz1021</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rayamajhi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shahi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maharjan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sudhir Suman</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Muscle Infiltrative Adult Multisystem Langerhans Cell Histiocytosis Detected on Fluorodeoxyglucose Positron Emission Tomography/computed Tomography - A Rare Case</article-title>. <source>Indian J.&#x20;Nucl. Med.</source> <volume>35</volume>, <fpage>342</fpage>&#x2013;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.4103/ijnm.IJNM_88_20</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reimand</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Isserlin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Voisin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kucera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tannus-Lopes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rostamianfar</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Pathway Enrichment Analysis and Visualization of Omics Data Using g:Profiler, GSEA, Cytoscape and EnrichmentMap</article-title>. <source>Nat. Protoc.</source> <volume>14</volume>, <fpage>482</fpage>&#x2013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1038/s41596-018-0103-9</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Phipson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Limma powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies</article-title>. <source>Nucleic Acids Res.</source> <volume>43</volume>, <fpage>e47</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>G. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>EdgeR: a Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data</article-title>. <source>Bioinformatics</source> <volume>26</volume>, <fpage>139</fpage>&#x2013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Graziano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>De Laurenzi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pascale</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Turco</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>BAG3: a Multifaceted Protein that Regulates Major Cell Pathways</article-title>. <source>Cel Death Dis</source> <volume>2</volume>, <fpage>e141</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2011.24</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Markiel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozier</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.&#x20;T.</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks</article-title>. <source>Genome Res.</source> <volume>13</volume>, <fpage>2498</fpage>&#x2013;<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gable</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Junge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huerta-Cepas</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-wide Experimental Datasets</article-title>. <source>Nucleic Acids Res.</source> <volume>47</volume>, <fpage>D607</fpage>&#x2013;<lpage>D613</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Therneau</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A Package for Survival Analysis in R. R Package Version 3.2-7</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survival/%20">https://CRAN.R-project.org/package&#x3d;survival/</ext-link> (Accessed March 20, 2021)</comment>. </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K.-Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>14-3-3&#x3b6; Promotes Esophageal Squamous Cell Carcinoma Invasion by Repressing S1PR2 Protein Expression through NF-&#x39a;b Signaling</article-title>. <source>Arch. Biochem. Biophys.</source> <volume>643</volume>, <fpage>7</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2018.02.009</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>Enhanced Expression of Circular RNA Circ-DCAF6 Predicts Adverse Prognosis and Promotes Cell Progression via Sponging miR-1231 and miR-1256 in Gastric Cancer</article-title>. <source>Exp. Mol. Pathol.</source> <volume>110</volume>, <fpage>104273</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexmp.2019.104273</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The Regulation of Acetylation and Stability of HMGA2 via the HBXIP-Activated Akt-PCAF Pathway in Promotion of Esophageal Squamous Cell Carcinoma Growth</article-title>. <source>Nucleic Acids Res.</source> <volume>48</volume>, <fpage>4858</fpage>&#x2013;<lpage>4876</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa232</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>Circular RNA circTADA2A Promotes Osteosarcoma Progression and Metastasis by Sponging miR-203a-3p and Regulating CREB3 Expression</article-title>. <source>Mol. Cancer</source> <volume>18</volume>, <fpage>73</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-019-1007-1</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Circular RNA Circ-ITCH Inhibits Bladder Cancer Progression by Sponging miR-17/miR-224 and Regulating P21, PTEN Expression</article-title>. <source>Mol. Cancer</source> <volume>17</volume>, <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-018-0771-7</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Poly (C)-binding Protein 2 (PCBP2) Promotes the Progression of Esophageal Squamous Cell Carcinoma (ESCC) through Regulating Cellular Proliferation and Apoptosis</article-title>. <source>Pathol. - Res. Pract.</source> <volume>212</volume>, <fpage>717</fpage>&#x2013;<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1016/j.prp.2016.05.008</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.-G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.-Y.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>ClusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters</article-title>. <source>OMICS: A J.&#x20;Integr. Biol.</source> <volume>16</volume>, <fpage>284</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling</article-title>. <source>Front. Oncol.</source> <volume>10</volume>, <fpage>580029</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.580029</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Overexpression of LIMD2 Promotes the Progression of Non-small C-ell L-ung C-ancer</article-title>. <source>Oncol. Lett.</source> <volume>18</volume>, <fpage>2073</fpage>&#x2013;<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10473</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Circular RNA_LARP4 Inhibits Cell Proliferation and Invasion of Gastric Cancer by Sponging miR-424-5p and Regulating LATS1 Expression</article-title>. <source>Mol. Cancer</source> <volume>16</volume>, <fpage>151</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-017-0719-3</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Immune Suppressive Landscape in the Human Esophageal Squamous Cell Carcinoma Microenvironment</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>6268</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20019-0</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pache</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khodabakhshi</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Tanaseichuk</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>1523</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>